Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock
Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.